Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia

  • Authors: Pshenichnaya NY1, Bulgakova VA2,3,4, Volchkova EV3, Kareva EN3,5, Selkova EP6, Gorodin VN1,7
  • Affiliations:
    1. Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases”
    2. Federal State Autonomous Institution “National Medical Research Center for Children's Health”
    3. Federal State Autonomous Educational Institution of the High Education “Sechenov First Moscow State Medical University” (Sechenov University)
    4. Federal State Budgetary Educational Institution of the High Education “Pirogov Russian National Research Medical University” (Pirogov Medical University)
    5. Federal State Budgetary Educational Institution of the High Education “Pirogov Russian National Research Medical University” (Pirogov Medical University)
    6. Federal State Budgetary Institution of Science “Moscow Research Institute of Epidemiology and Microbiology” of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing
    7. Kuban State Medical University (KubSMU)
  • Issue: Vol 91, No 11 (2019)
  • Pages: 105-109
  • Section: Editorial
  • URL: https://journals.rcsi.science/0040-3660/article/view/33719
  • DOI: https://doi.org/10.26442/00403660.2019.11.000454
  • ID: 33719

Cite item

Full Text

Abstract

Aim: to determine the perspectives for the use of drugs with combined antiviral, anti - inflammatory and immunomodulatory activity on the basis of medical studies of existing antiviral drugs for the treatment of influenza and acute respiratory viral infections in Russia. Materials and methods. A brief review of the antiviral drugs used in Russia for the treatment of influenza and acute respiratory viral infections was conducted on the basis of 37 articles published in Scopus, Web of Science (WoS), and RSCI databases in the period from 1997 to 2018. Results. Resistance to neuraminidase inhibitors (oseltamivir, zanamivir), is slowly developing due to the mutations of the neuraminidase gene H275Y and Q136K. Most influenza A viruses remain resistant to adamantane antivirals. Repeated use of immunomodulators with indirect antiviral action leads to a hyporeactivity of the immune system and, subsequently, to a decrease in their effectiveness. Positive clinical and laboratory data in clinical trials were obtained using Enisamium iodide, a drug with combined action - direct antiviral, and immunomodulatory. Conclusion. According to the WHO strategy, the results of the review demonstrate the need for continued research of medications with combined antiviral and pathogenetic effects on the infectious process caused by influenza and acute respiratory viral infections.

About the authors

N Y Pshenichnaya

Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases”

Email: natalia-pshenichnaya@yandex.ru
д.м.н., проф., руководитель международного отдела по оказанию медицинской помощи ФГБУ «НМИЦ ФПИ» Минздрава России; ORCID: 0000-0003-2570-711X Moscow, Russia

V A Bulgakova

Federal State Autonomous Institution “National Medical Research Center for Children's Health”; Federal State Autonomous Educational Institution of the High Education “Sechenov First Moscow State Medical University” (Sechenov University); Federal State Budgetary Educational Institution of the High Education “Pirogov Russian National Research Medical University” (Pirogov Medical University)

д.м.н., г. н. с. отд. прогнозирования и планирования научных исследований ФГАУ «НМИЦ здоровья детей» Минздрава России; проф. каф. педиатрии и детской ревматологии педиатрического фак-та ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет); проф. каф. факультетской педиатрии педиатрического фак-та ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России, ORCID: 0000-0003-4861-0919 Moscow, Russia

E V Volchkova

Federal State Autonomous Educational Institution of the High Education “Sechenov First Moscow State Medical University” (Sechenov University)

д.м.н., проф., зав. каф. инфекционных болезней ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0003-4581-4510 Moscow, Russia

E N Kareva

Federal State Autonomous Educational Institution of the High Education “Sechenov First Moscow State Medical University” (Sechenov University); Federal State Budgetary Educational Institution of the High Education “Pirogov Russian National Research Medical University” (Pirogov Medical University)

д.м.н., проф., проф. каф. молекулярной фармакологии и радиобиологии им. академика П.В. Сергеева МБФ ГБУ ВПО «РНИМУ им. Н.И. Пирогова» Минздрава России; проф. каф. фармакологии ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России (Сеченовский Университет), ORCID: 0000-0002-9441-3468 Moscow, Russia

E P Selkova

Federal State Budgetary Institution of Science “Moscow Research Institute of Epidemiology and Microbiology” of Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing

д.м.н., проф., зам. директора ФБУН «МНИИЭМ им. Г.Н. Габричевского» Роспотребнадзора Moscow, Russia

V N Gorodin

Federal State Budgetary Institution “National Medical Research Center for Phthisiopulmonology and Infectious Diseases”; Kuban State Medical University (KubSMU)

д.м.н., проф., зам. директора ФГБУ «НМИЦ ФПИ» Минздрава России; зав. каф. инфекционных болезней и эпидемиологии «КубГМУ» Минздрава России, ORCID: 0000-0003-3062-7595 Moscow, Russia

References

  1. Johnson N.P.A.S, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002;76(1):105-15. doi: 10.1353/bhm.2002.0022
  2. Spreeuwenberg P, Kroneman M, Paget J. Reassessing the global mortality burden of the 1918 influenza pandemic. Am J Epidemiol. 2018;187(12):2561-7. doi: 10.1093/aje/kwy191
  3. Iuliano A.D, Roguski K.M, Chang H.H, Muscatello D.J, Palekar R, Tempia S, et al. Estimates of global seasonal influenza - associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285-300. doi:10.1016/ S0140-6736(17)33293-2
  4. Global influenza strategy 2019-2030. Geneva: World Health Organization, 2019. https://apps.who.int/iris/bitstream/handle/10665/311184/ 9789241515320-eng.pdf?ua=1 [Accessed 20.07.2019]
  5. О состоянии санитарно - эпидемиологического благополучия населения в Российской Федерации в 2018 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2019:254 с.
  6. Руженцова Т.А. Протививорусные ЛС и иммуномодуляторы в терапии ОРВИ. Путеводитель врачебных назначений. Бионика Медиа. 2017;5.
  7. Shinahara W, Takahashi E, Sawabuchi T, Arai M, Hirotsu N, Takasaki Y, et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re - infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. PloS ONE. 2013;8(7):e70060. doi: 10.1371/journal.pone.0070060
  8. Sheu T.G, Fry A.M, Garten R.J, Deyde V.M, Shwe T, Bullion L, et al. Dual resistance to adamantanes and oseltamivir among seasonal influenza A (H1N1) viruses: 2008-2010. J Infectious Diseases. 2011;203(1):13-7. doi: 10.1093/inf dis/jiq005
  9. Spencer S, Nguyen H, Elal A.A, Laplante J, St George K, Fry A.M, et al. Surveillance for Oseltamivir-Resistant Influenza A (H1N1) pdm09 Virus Infections During 2016-2017 and 2017-2018, United States. In Open Forum Infectious Diseases. 2018;5(Suppl 1):S267. doi: 10.1093/ofid/ofy210.752
  10. Bragstad K, Hungnes O, Litleskare I, Nyrerød H.C, Dorenberg D.H, Hauge S.H. Community spread and late season increased incidence of oseltamivir - resistant influenza A (H1N1) viruses in Norway 2016. Influenza and other respiratory viruses. 2019;13(4):372-81. doi: 10.1111/irv.12637
  11. Hurt A.C, Holien J.K, Parker M, Kelso A, Barr I.G. Zanamivir - resistant influenza viruses with a novel neuraminidase mutation. J Virology. 2009; 83(20):10366-73. doi: 10.1128/JVI.01200-09
  12. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clinical infectious diseases. 2009;50(4):620. doi:10. 1086/650176
  13. Dong G, Peng C, Luo J, Wang C, Han L, Wu B. Adamantane - resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PloS ONE. 2015;10(3):e0119115. doi: 10.1371/journal.pone.01 19115
  14. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine - treated children with influenza. J Infectious Diseases. 2003;188(1):57-61. doi: 10.1086/375799
  15. Булгакова В.А., Поромов А.А., Грекова А.И., Пшеничная Н.Ю., Селькова Е.П., Львов Н.И., Малеев, В.В. Фармакоэпидемиологическое исследование течения гриппа и других ОРВИ в группах риска. Терапевтический архив. 2017;89(1):62-71. doi: 10.17116/terarkh201789162-71
  16. Ратникова Л. И. Применение нового отечественного противовирусного препарата в этиотропной терапии гриппа. Экспериментальная и клиническая фармакология. 2018;81(3):24-7.
  17. Ramos I, Fernandez-Sesma A. Modulating the innate immune response to influenza A virus: potential therapeutic use of anti - inflammatory drugs. Frontiers in immunology. 2015;(6):361. doi: 10.3389/fimmu.2015.00361
  18. Бухтiарова Т.А. Амiзон - новий неопiоїдний анальгетик з протизапальними, жарознижуючими та iнтерфероногенними властивостями. Лiки. 1997;3:69.
  19. Фролов А.Ф., Фролов В.М. Эффективность Амизона в лечении и профилактике вирусных инфекций (к 10-летию применения препарата в клинической практике). Український медичний часопис. 2005;49(5)-ІХ/Х: 75-80.
  20. Исаков В.А., Охапкина Е.А., Евграфов В.Д. Эффективность амизона в терапии и профилактике ОРВИ. Медицинский форум. 2015.
  21. Boltz D, Peng X, Muzzio M, Dash P, Thomas P, Mehta R, Margitich V. Antiviral activity of enisamium against influenza viruses in differentiated normal human bronchial epithelial cells. In III antivirus congress. Amsterdam, October 2014:12-14.
  22. Cocking D, Cinatl J, Boltz D.A, Peng X, Johnson W, et al. Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta virologica. 2018;62(2):191-5. doi: 10.4149/av_2018_2 11
  23. Денисова А.Р., Максимов М.Л. Острые респираторные вирусные инфекции: этиология, диагностика, современный взгляд на лечение. РМЖ. Медицинское обозрение. 2018;1(II):99-103.
  24. Фролов А.Ф., Фролов В.М., Бухтиарова Т.А., Даниленко В.Ф. Клинические аспекты применения Амизона. Украинский медицинский журнал. 2004;39(1):69-74.
  25. Нобазит, инструкция по применению. Интернет - ресурс. http://www.grls.rosminzdrav. ru/Grls_View_v2.aspx?routingGuid=fd084d2c-63a4-4360-bb5b-281e98c9c241 &t=2d3c9fcf-1833-4c0e-8c37-82b0f568fa4d [Accessed 20.07.2019].
  26. Мельникова Т.И., Деева Э.Г., Амосова И.В., Оксамитная Е.Г., Маргитич В.М. Клиническая эффективность Амизона в терапии гриппа и других острых респираторных вирусных инфекций. Здоров’я Украiни. 2013;17:40-1.
  27. Сенцова Т.Б., Ревякина В.А., Ворожко И.В., Кириллова О.О., Моносова О.Ю. Современные аспекты применения иммуномодуляторов в лечении и профилактике респираторных вирусных инфекций у детей. Вопросы практической педиатрии. 2011;6(5):100-4.
  28. Исаков Д.В., Исаков В.А., Алексеева Е.А. Иммуномодуляторы в терапии и профилактике респираторных и герпесвирусных инфекций. Клиническая фармакология и терапия. 2018;27(5):76-85.
  29. Савенкова М.С, Савенков М.П, Афанасьева А.А, Абрамова Н.А. Возможности противовирусной и иммуномодулирующей терапии в лечении гриппа, ОРВИ, герпесвирусных инфекций. Пульмонология. 2015; (5):83-93.
  30. Li W, Moltedo B, Moran T.M. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of γδ T-cells. J Virology. 2012;86(22):12304-12. doi: 10.1128/JVI.01269-12
  31. Killip M.J, Fodor E, Randall R.E. Influenza virus activation of the interferon system. Virus research. 2015;209:11-22. doi: 10.1016/j.virusres.2015.02.003
  32. Taylor R.T, Bresnahan W.A. Human cytomegalovirus immediate - early 2 gene expression blocks virus - induced beta interferon production. J Virology. 2005;79(6):3873-7. doi: 10.1128/JVI.79.6.3873-3877.2005
  33. Minamitani T, Iwakiri D, Takada K. Adenovirus virus - associated RNAs induce type I interferon expression through a RIG-I-mediated pathway. J Virology. 2011;85(8):4035-40. doi: 10.1128/JVI.02160-10
  34. Hermodsson S. Inhibition of interferon by an infection with parainfluenza virus type 3 (PIV-3). J Virology. 1963;20(2):333-43. doi: 10.1016/0042-6822(63) 90123-5
  35. Peng T, Kotla S, Bumgarner R.E, Gustin K.E. Human rhinovirus attenuates the type I interferon response by disrupting activation of interferon regulatory factor 3. J Virology. 2006;80(10):5021-31. doi: 10.1128/JVI.80.10.5021-5031. 2006
  36. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+ CD4+ regulatory T-cells through GITR breaks immunological self - tolerance. Nature immunology. 2002;3(2):135.
  37. Интерфероногены: перспективы клинического применения: Руководство для врачей. Под ред. М.Г. Романцова. М., СПб., 1998:38 с.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies